The Medical Device Authority of Malaysia has approved Altamira Therapeutics Ltd's (NASDAQ: CYTO) Bentrio.

• "We are very pleased with the swift 'go-to-market' progress in Malaysia and Singapore," commented Thomas Meyer, Founder, Chairman, and CEO. As previously indicated, we expect Bentrio sales in Asian markets to contribute to our 2022 revenues significantly."

• Bentrio (AM-301) is a drug-free nasal spray intended for personal protection against airborne viruses and allergens.

• The spray forms a protective gel layer on the nasal mucosa upon application into the nose, designed to prevent the contact of viruses or allergens with cells.

• In human nasal epithelium cells infected by COVID-19, Bentrio reduced the infectious viral load by more than 99% when used for prevention.

• Further, Bentrio effectively slowed the growth of the viral titer when treatment started only 24 or 30 hours after infection.

• In allergy, a clinical investigation in a pollen challenge chamber demonstrated a significant reduction in the main symptoms of allergic rhinitis with the protective effect setting in rapidly and lasting for 4 hours.

• Price Action: CYTO shares are down 8.22% at $1.34 during the market session on the last check Friday.

See more from Benzinga

• Tennis Player Novak Djokovic Holds Majority Stake In European Biotech Working On COVID-19 Treatment

• Alnylam' Reveals Detailed 18-Month Data From Vutrisiran Trial In Inherited Disease

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.